Kennedy Capital Management LLC Boosts Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Kennedy Capital Management LLC increased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 20.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 321,526 shares of the company's stock after buying an additional 54,493 shares during the period. Kennedy Capital Management LLC owned about 0.54% of Protagonist Therapeutics worth $12,411,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. FNY Investment Advisers LLC bought a new position in Protagonist Therapeutics during the 4th quarter worth about $38,000. KBC Group NV increased its holdings in Protagonist Therapeutics by 54.4% during the fourth quarter. KBC Group NV now owns 2,093 shares of the company's stock valued at $81,000 after buying an additional 737 shares during the period. Nisa Investment Advisors LLC raised its stake in Protagonist Therapeutics by 10.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock worth $121,000 after buying an additional 295 shares in the last quarter. Cibc World Markets Corp bought a new position in Protagonist Therapeutics in the fourth quarter worth approximately $211,000. Finally, Caprock Group LLC purchased a new stake in Protagonist Therapeutics during the fourth quarter worth $224,000. Hedge funds and other institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Trading Up 2.9 %

Shares of NASDAQ:PTGX traded up $1.31 on Tuesday, hitting $46.34. 997,637 shares of the company were exchanged, compared to its average volume of 833,349. The stock's 50 day moving average price is $44.19 and its 200 day moving average price is $42.74. Protagonist Therapeutics, Inc. has a 1-year low of $24.22 and a 1-year high of $60.60. The firm has a market capitalization of $2.84 billion, a P/E ratio of 17.42 and a beta of 2.30.

Remove Ads

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its earnings results on Friday, February 21st. The company reported $1.98 EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $2.07. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The firm had revenue of $170.64 million during the quarter, compared to the consensus estimate of $56.65 million. On average, equities analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PTGX has been the subject of several recent research reports. Wedbush reissued an "outperform" rating and issued a $70.00 price target on shares of Protagonist Therapeutics in a research report on Friday, March 28th. BMO Capital Markets boosted their target price on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Truist Financial raised their price target on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the company a "buy" rating in a report on Tuesday, March 11th. JPMorgan Chase & Co. raised their target price on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Protagonist Therapeutics in a research report on Thursday, April 10th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $65.44.

Insider Buying and Selling at Protagonist Therapeutics

In related news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $38.18, for a total transaction of $204,606.62. Following the sale, the chief executive officer now directly owns 540,260 shares of the company's stock, valued at approximately $20,627,126.80. This represents a 0.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director William D. Waddill sold 4,000 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the completion of the transaction, the director now owns 13,130 shares of the company's stock, valued at approximately $712,302.50. This trade represents a 23.35 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 64,776 shares of company stock worth $3,585,010. Company insiders own 5.40% of the company's stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.